A Historic Milestone on the Path to Full Healthcare Independence: Türkiye’s First National Pharmaceutical R&D Company TRUSTLIFE Submits Clinical Application for Its Indigenous Alzheimer’s Drug
In line with Türkiye’s strategic goal of achieving full independence in health technologies, a Phase I clinical trial application has been submitted to the Turkish Medicines and Medical Devices Agency (TİTCK) for an Alzheimer’s drug developed by Turkish scientists.
It was announced that the drug candidate, developed through the collaboration between TRUSTLIFE—Türkiye’s national health technologies platform—and Atatürk University, has completed all research and development stages from discovery to clinical application entirely within Türkiye.
This application marks a historic first step, representing the transition of an original molecule developed in Türkiye into the clinical research phase.TRUSTLIFE reported that it currently manages 15 domestic drug development projects across various disease areas, and that Phase I applications are planned for the five candidates closest to clinical readiness.
The first application has now been submitted for the Alzheimer’s drug, while all preparations for the remaining four drug candidates have been finalized and will be submitted to TİTCK within the first half of 2026.
Following the Phase I submission, a visit was made to TİTCK President Prof. Dr. Ahmet Ayar. The delegation included TRUSTLIFE Executive Board Chair Dr. Bülent Denkdemir; Trustlife Science Team leaders Prof. Dr. Adil Mardinoğlu and Prof. Dr. Hasan Türkez; Atatürk University Rector Prof. Dr. Ahmet Hacımüftüoğlu; and TRUSTLIFE Executive Board Member Dr. Erkan Mankan. The meeting addressed strategies to accelerate clinical research processes for Türkiye’s domestically developed drugs, strengthen national drug development capacity, and position Türkiye as a globally influential player in health technologies.
